Lin Yang

Lin Yang

Auto-generated profile, based on publicly available information

Lin Yang

Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center (L.Y., K.S., E.G., S.M.D., G.J.W., A.S.N., L.A.E., H.M.J., T.J.K., P.W.G., J.G., A.C.F.), Perelman School of Medicine, University of Pennsylvania, Philadelphia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2021 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
ANAshwin S. Nathan
Ashwin S. Nathan
LYLin Yang
Lin Yang
NYNancy Yang
Nancy Yang
SKSameed Ahmed M. Khatana
Sameed Ahmed M. Khatana
EDElias J. Dayoub
Elias J. Dayoub
AFAlexander C. Fanaroff
Alexander C. Fanaroff
Background: Despite the benefits of novel therapeutics, inequitable diffusion of new technologies may generate disparities. We examined the growth of transcatheter aortic valve replacement (TAVR) in the United States to understand the characteristics of hospitals that developed TAVR programs and the socioeconomic status of patients these hospitals served. Methods: We identified fee-for-service Medicare beneficiaries aged 66 years or older who underwent TAVR between January 1, 2012, and December 31, 2018, and hospitals that developed TAVR programs (defined as performing ≥10 TAVRs over the study period). We used linear regression models to compare socioeconomic characteristics of patients treated at hospitals that did and did not establish TAVR programs and described the association between core-based statistical area level markers of socioeconomic status and TAVR rates. Results: Between 2012 and 2018, 583 hospitals developed new TAVR programs, including 572 (98.1%) in metropolitan areas, and 293 (50.3%) in metropolitan areas with preexisting TAVR programs. Compared with hospitals that did not start TAVR programs, hospitals that did start TAVR programs treated fewer patients with dual eligibility for Medicaid (difference of −2.83% [95% CI, −3.78% to −1.89%], P ≤0.01), higher median household incomes (difference $2447 [95% CI, $1348–$3547], P =0.03), and from areas with lower distressed communities index scores (difference −4.02 units [95% CI, −5.43 to −2.61], P ≤0.01). After adjusting for the age, clinical comorbidities, race and ethnicity and socioeconomic status, areas with TAVR programs had higher rates of TAVR and TAVR rates per 100 000 Medicare beneficiaries were higher in core-based statistical areas with fewer dual eligible patients, higher median income, and lower distressed communities index scores. Conclusions: During the initial growth phase of TAVR programs in the United States, hospitals serving wealthier patients were more likely to start programs. This pattern of growth has led to inequities in the dispersion of TAVR, with lower rates in poorer communities.

16 November 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
TMTimothy M. Markman
Timothy M. Markman
CBChase R. Brown
Chase R. Brown
LYLin Yang
Lin Yang
GGGustavo S. Guandalini
Gustavo S. Guandalini
MHMatthew C. Hyman
Matthew C. Hyman
DFDavid S. Frankel
David S. Frankel
Background: Prescription opioids are a major contributor to the ongoing epidemic of persistent opioid use (POU). The incidence of POU among opioid-naïve patients after cardiac implantable electronic device (CIED) procedures is unknown. Methods: This retrospective cohort study used data from a national administrative claims database from 2004 to 2018 of patients undergoing CIED procedures. Adult patients were included if they were opioid-naïve during the 180-day period before the procedure and did not undergo another procedure with anesthesia in the next 180 days. POU was defined by filling an additional opioid prescription >30 days after the CIED procedure. Results: Of the 143 400 patients who met the inclusion criteria, 15 316 (11%) filled an opioid prescription within 14 days of surgery. Among these patients, POU occurred in 1901 (12.4%) patients 30 to 180 days after surgery. The likelihood of developing POU was increased for patients who had a history of drug abuse (odds ratio, 1.52; P =0.005), preoperative muscle relaxant (odds ratio, 1.52; P <0.001) or benzodiazepine (odds ratio, 1.23; P =0.001) use, or opioid use in the previous 5 years (OR, 1.76; P 135 mg of oral morphine equivalents had a significantly increased risk of POU. Conclusions: POU is common after CIED procedures, and 12% of patients continued to use opioids >30 days after surgery. Higher initially prescribed oral morphine equivalent doses were associated with developing POU.

1 January 2025 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
OROmar I. Ramadan
Omar I. Ramadan
LYLin Yang
Lin Yang
KSKaitlyn Shultz
Kaitlyn Shultz
EGElizabeth Genovese
Elizabeth Genovese
SDScott M. Damrauer
Scott M. Damrauer
AFAlexander C. Fanaroff
Alexander C. Fanaroff
BACKGROUND: Black patients, those with low socioeconomic status (SES), and those living in rural areas have elevated rates of major lower extremity amputation, which may be related to a lack of subspecialty chronic limb-threatening ischemia care. We evaluated the association between race, rurality, SES, and preamputation vascular care. METHODS: Among patients aged 66 to 86 years with fee-for-service Medicare who underwent major lower extremity amputation for chronic limb-threatening ischemia from July 2010 to December 2019, we compared the proportion who received vascular care in the 12 months before amputation by race (Black versus White), rurality, and SES (dual eligibility for Medicaid versus no dual eligibility) using multivariable logistic regression adjusting for clinical and demographic covariates. RESULTS: Among 73 237 patients who underwent major lower extremity amputation, 40 320 (55.1%) had an outpatient vascular subspecialist visit, 60 109 (82.1%) had lower extremity arterial testing, and 28 345 (38.7%) underwent lower extremity revascularization in the year before amputation. Black patients were less likely to have an outpatient vascular specialist visit (adjusted odds ratio [adjOR], 0.87 [95% CI, 0.84–0.90]) or revascularization (adjOR, 0.90 [95% CI, 0.86–0.93]) than White patients. Compared with patients without low SES or residing in urban areas, patients with low SES or residing in rural areas were less likely to have an outpatient vascular specialist visit (adjOR, 0.62 [95% CI, 0.60–0.64]; low SES versus nonlow SES; adjOR, 0.82 [95% CI, 0.79–0.85]; rural versus urban), lower extremity arterial testing (adjOR, 0.78 [95% CI, 0.75–0.81]; low SES versus nonlow SES; adjOR, 0.90 [95% CI, 0.0.86–0.94]; rural versus urban), or revascularization (adjOR, 0.65 [95% CI, 0.63–0.67]; low SES versus nonlow SES; adjOR, 0.89 [95% CI, 0.86–0.93]; rural versus urban). CONCLUSIONS: Black race, rural residence, and low SES are associated with failure to receive subspecialty chronic limb-threatening ischemia care before amputation. To reduce disparities in amputation, multilevel interventions to facilitate equitable chronic limb-threatening ischemia care are needed.

7 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
AFAlexander C. Fanaroff
Alexander C. Fanaroff
EDElias J. Dayoub
Elias J. Dayoub
LYLin Yang
Lin Yang
KSKaitlyn Schultz
Kaitlyn Schultz
OROmar I. Ramadan
Omar I. Ramadan
JGJay S. Giri
Jay S. Giri
Background: The extent and consequences of ischemia in patients with chronic limb‐threatening ischemia (CLTI) may change rapidly, and delays from diagnosis to revascularization may worsen outcomes. We sought to describe the association between time from diagnosis to endovascular lower extremity revascularization (diagnosis‐to‐limb revascularization [D2L] time) and clinical outcomes in outpatients with CLTI. Methods and Results: In the CLIPPER cohort, comprising patients between 66 and 86 years old diagnosed with CLTI betweeen 2010 and 2019, we used Medicare claims data to identify patients who underwent outpatient endovascular revascularization within 180 days of diagnosis. We described the risk‐adjusted association between D2L time and clinical outcomes. Among 1 130 065 patients aged between 66 and 86 years with CLTI, 99 221 (8.8%) underwent outpatient endovascular lower extremity revascularization within 180 days of their CLTI diagnosis. Among patients with D2L time 30 days, each additional 10‐day increase in D2L time was associated with a 2.5% greater risk of major amputation (hazard ratio, 1.025 [95% CI, 1.014–1.036]). There was no association between D2L time and all‐cause death. Conclusions: A delay of >30 days from CLTI diagnosis to lower extremity endovascular revascularization was associated with an increased risk of major lower extremity amputation among patients undergoing outpatient endovascular revascularization. Improving systems of care to reduce D2L time could reduce amputations.

25 July 2011 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
PGPeter W. Groeneveld
Peter W. Groeneveld
DPDaniel Polsky
Daniel Polsky
FYFeifei neuron network Feifei Yang
Feifei neuron network Feifei Yang
LYLin Yang
Lin Yang
AEAndrew J. Epstein
Andrew J. Epstein
Drug-eluting coronary stents (DESs) are widely used1 and entail sizeable Medicare hospital expenditures.2 However, the overall cost impact of DESs has not been well quantified. A clear understanding of how new technologies like DESs affect health care expenditures can provide insight into national trends in health care cost growth, of which new technology is presumably the leading driver.3 New technology may not only increase costs by being more expensive than previous treatments, but also by changing the patterns of care for chronic disease.4 Accordingly, we sought to assess the overall impact of DESs on Medicare expenditures in a nationally representative cohort of Medicare beneficiaries with coronary artery disease (CAD).